AzTrials
AzTrials

Joint StabiliotyPhase 4NCT02855294

The Effect of Oral Contraceptives on Women Balance

A Phase 4 study testing COC containing 30 μg of EE and 3mg of drospirenone in people with Joint Stabilioty, run by Cairo University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

1. Recording Data Sheet: All data and information of each woman in both groups (A \& B) participated in this study were recorded in a recording data sheet (Appendix II). 2. Weight-Height scale: A valid and reliable weight -height scale, with a range of 1 to 150 kilograms weight, and 1 to 200 centimeters height was… Read more about this study

Who is it for?
Ages 20 to 40 years, women onlyHealthy volunteers can take part
Conditions the study is for
Joint Stabilioty
What is being tested?
COC containing 30 μg of EE and 3mg of drospirenone
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteEgypt
Study dates
Jan 2015to Jul 2016
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 40 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • All women in group (A) had takenthe oral contraceptive pill have done so routinely for the past three months.
  • All women in group (B) had a normal menstrual cycle; use any other non-hormonal contraceptive method.
  • Their body mass index did not exceed 30 Kg/m2.
  • All women had a normal menstrual cycle of 25-32 days for the past 3 months.
  • They can stand independently.

Who cannot join

  • Respiratory or heart problems.
  • Skeletal deformityorusing assistive devices.
  • Visual and vestibular system affection.
  • Cognition problems.
  • Previous surgeries at their back and/or lower limbs.
  • Genital and breast cancer and active liver disease.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Kasr Alainy medical school

    Cairo, Cairo Governorate, 12151

Other trials in Egypt

About this study

Official title: The Effect of Oral Contraceptives on Dynamic Balance in Women

  1. Recording Data Sheet: All data and information of each woman in both groups (A \& B) participated in this study were recorded in a recording data sheet (Appendix II).
  2. Weight-Height scale: A valid and reliable weight -height scale, with a range of 1 to 150 kilograms weight, and 1 to 200 centimeters height was used to measure the relevant subject's data.
  3. Siemens Immulite Immunoassay System: (Siemens Medical Solutions Diagnostics Immulite 1000,Los Angles, CA, 900-456900 U.S.A) to measure the serum Progesterone and Estradiol levels in both groups (A\& B) using (TKE 21 Kit) for Estradiol and (TKPG 1 Kit) for Progesterone.
  4. Biodex balance system:

Biodex Balance System (BBS), P.O. Box 702, Shirley, Ny 11967.It is an apparatus used to measure the dynamic balance. It utilizes dynamic multi axial platform. This platform allows approximately 20 degree inclination in 360 degree range and is interfaced with computer software. It measures the patient's ability to control the platform's angle of tilt, which is quantified as a variance from the center, as well as the degree of deflection over time at various stability levels as shown in (Fig. 6).

Read more

Stability levels allowed by the system ranged from one to eight. Stability level 8, allows the highest level of stability as it makes the platform to be the least tilted. On the other hand, stability level one represents the least level of stability and is more difficult for the subject to maintain stability on.

The test consists of recording the patient's ability to control the platform variance from a perfectly balanced position. A large variance is indicative of poor control and balance. Further definition is realized with the quantification of Anterior/ Posterior and Medial/Lateral responses.

Read the detailed description
  1. Recording Data Sheet: All data and information of each woman in both groups (A \& B) participated in this study were recorded in a recording data sheet.
  2. Weight-Height scale: A valid and reliable weight -height scale, with a range of 1 to 150 kilograms weight, and 1 to 200 centimeters height was used to measure the relevant subject's data.
  3. Siemens Immulite Immunoassay System: (Siemens Medical Solutions Diagnostics Immulite 1000,Los Angles, CA, 900-456900 U.S.A) to measure the serum Progesterone and Estradiol levels in both groups (A\& B) using (TKE 21 Kit) for Estradiol and (TKPG 1 Kit) for Progesterone.
  4. Biodex balance system:

Biodex Balance System (BBS), P.O. Box 702, Shirley, Ny 11967.It is an apparatus used to measure the dynamic balance. It utilizes dynamic multi axial platform. This platform allows approximately 20 degree inclination in 360 degree range and is interfaced with computer software. It measures the patient's ability to control the platform's angle of tilt, which is quantified as a variance from the center, as well as the degree of deflection over time at various stability levels as shown in .

Stability levels allowed by the system ranged from one to eight. Stability level 8, allows the highest level of stability as it makes the platform to be the least tilted. On the other hand, stability level one represents the least level of stability and is more difficult for the subject to maintain stability on.

The test consists of recording the patient's ability to control the platform variance from a perfectly balanced position. A large variance is indicative of poor control and balance. Further definition is realized with the quantification of Anterior/ Posterior and Medial/Lateral responses.

The BBS Consists of the Following:

  • Display Screen: Its height can be adjusted from 51cm to 68 cm above the platform. Display angle of the screen can be adjusted from vertical back up to 45º. Display viewing area: 122 mms x 92 mms. Display accuracy: ±1 degree of tilt.
  • Support Handle Rails: Adjustable from 125 cm to 136.5 cm above the platform. The rails can be swung away from the platform if desired.
  • Platform: Its height is 8 cm above floor, with a diameter of 21.5 cm. The platform has a grid which consists of two coordinates: X and Y. The platform X coordinate is marked in numbers from 1 to 21, whereas the platform Y coordinate is marked in letters from A to P, the platform is also marked in angles from 0º to 45º, for precise feet placement and documentation of the subject during the test procedures .
  • Printer: Cannon Bubble-Jet Printer, centronics parallel interface.

Stability levels:

  • Biodex balance system has been allowed for eight stability levels, which has been ranged from stability level (1) to stability level (8).which allows setting up of the test parameters.

Stability indices:

  • The woman's ability to control the platform's angle of tilt measured by the system.The woman's performance wasnoted as a stability index.
  • The stability index represents the variance of platform displacement in degrees from level. A high number is an indicative of a lot of motion, which indicates balance problem.
  • The data regarding the balance of the tested woman were supplied to the system. These data includesantero-posterior stability index (APSI), medio-lateral stability index (MLSI) \&overall stability index (OSI).
  • On the upper most part of the surface of the platform appear angles from 0o to 95o with the lines which represents these angles. These lines would be used to measure foot angle.
  • The smaller the amount of sway, the lower the numerical value of these indices.
  • Over all stability index (OSI): Represents the woman's ability to control her balance in all directions.
  • Anterior/Posterior stability index (APSI): Representsthe woman's ability to control her balance in front to back directions (sagittal plane).
  • Medial/Lateral stability index (MLSI): Represents the woman's ability to control her balance from side to side directions(frontal plane).

III-Methods:

The evaluation procedures were explained in details for every woman in both groups (A\&B) to increase her interest and co-operation.

Body Mass Index

The data of each woman in both groups were taken according to items of the recording data sheet then, the weight and height were measured and BMI was calculated according to the following equation BMI = Weight/Height (Kg/m2)

Blood sampling

Evening Blood sample was collected from each woman to limit the effect of hormone diurnal variations,For both groups samples have been collected at mid-luteal phase (20th to 23th days of the cycle), at Al-Madina Lab.

The sample was allowed to clot in water bath at room temperature.the serum was separated using a centrifuge at 4000 rmp for 15 min.Then using the TKE 21 and TKPG 1 Kits in a low temperature air conditioned room to measure serum Estradiol and Progesterone levels.

Biodex balance system:

The procedures were performed in dynamic balance lab at physical therapy faculty CairoUniversity.

Biodex Balance System used for assessment of the postural stability in female oral contraceptive users and non-users. The assessment was conducted for each woman individually.

The protocol of the work was explained to the woman before conducting this study.

  1. Biodex balance system:

Operating the balance system:

  • When the system is on, the first displayed screen showed the main menu. It allowed us to choose entering test or system utilities.
  • Choosing to enter testing showed the next screen, which allowed for determining the test parameters as test duration and the stability levels were chosen as the initial stability level (8) and the end stability level (4).
  • The next screen was used for centering process.
  • The next screen was the stability test screen. The start key was pressed while on this screen to unlock the platform allowing the test to start. A cursor appeared during the test tracing the movement of the platform while the timer counting till the time of the test ends.
  • The duration of test lasts for 20 seconds staring with stability level (8) and progressing the stability levels ending with stability level (4)
  • The foot platform automatically returned to the locked position. At this point, the investigators printed the screen, including the numeric value of the APSI, MLSI and OSI.

Testing Protocol:

  • Testing procedures was done at mid-luteal phase (20th to 23th days of the cycle). Each woman was received verbal explanation about the test steps.
  • The woman was tested without footwear and with eyes opened.
  • Two test trials was done before specific test condition for the purpose of instrument familiarity prior to data collection.
  • A high stability level (stability level 8) and reduced test time (20 sec) was chosen to avoid falling.
  • Each woman was asked to perform two trial tests and their mean was calculated.
  • Each test started with the balance platform in the locked position and standing on its center.

Preparatory step: the parameters of each examined woman (weight, height and age) as well as, test duration and stability level of the platform of the BBS were typed to the software of the device as shown in Fig. (8). All woman were asked to stand on the platform of the BBS in an erect posture as possible and kept it all through the test duration (i.e. stand on both feet, chin in, shoulders were leveled, as well as, retracted , back was straight and knees were drawn backward). Hence, the support handle rails and display screen were adjusted according to the height of each examined woman.

Centering step: with the aim of positioning the center of gravity (COG) of the subject at the middle of her base of support between the two feet and recoding the women's feet position. Centering was achieved by asking each woman to stand on the platform of the BBS while grasping the support handle rails by both hands while the platform was locked . Formerly, the platform was unlocked at stability level 8, the display screen showed a circle with a central cursor. At that time, the subject was asked to achieve a central position on the platform by shifting her feet position until she was able to keep the cursor (which represents the center of platform) centered on the circle that appeared on the display screen and correspondingly the platform was kept easily leveled.

  • Once centering was achieved and the cursor was in the center of the display screen, each woman was instructed to maintain her feet at that position constant until the end of test procedures. At that time, the platform was locked again to allow recording the feet angles and heel's coordinates from the platform grid. The heel's coordinates were determined by finding the location of the center of the back of each heel in relation to X and Y coordinates of the platform, while the feet angles were determined by finding a line on the platform parallel to the 2nd metatarsal bone of each foot. Then, the feet angles and heels coordinates for each womanwere entered to the software of the BBS
Being tested
COC containing 30 μg of EE and 3mg of drospirenone
Keywords
oral contraceptive pills, Joint stability

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • COC containing 30 μg of EE and 3mg of drospirenoneDrug

    Also called Yasmin; Schering AG, Berlin, Germany

    treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.

Study groups in NCT02855294
Study groupRoleWhat they receive
Oral contraceptive pills usersActive comparatorThe participants received treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of ring/pill treatment followed by a 1-week pill-free period. The women were randomized in a 1:1 ratio to receive the COC containing 30 μg of EE and 3mg of drospirenone (Yasmin; Schering AG, Berlin, Germany)
Receives: Drug: COC containing 30 μg of EE and 3mg of drospirenone
controlNo interventionno drugs

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. overall joint stability

    1. Biodex balance system:

    Testing procedures was done at mid-luteal phase (20th to 23th days of the cycle). Each woman was received verbal explanation about the test steps.

    The woman was tested without footwear and with eyes opened. Two test trials was done before specific test condition for the purpose of instrument familiarity prior to data collection.

    A high stability level (stability level 8) and reduced test time (20 sec) was chosen to avoid falling.

    Each woman was asked to perform two trial tests and their mean was calculated. Each test started with the balance platform in the locked position and standing on its center.

    Measured: 6 months after pill use

Secondary outcomes (1)
  1. side effects

    Measured: 6 months after pill use

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Aug 2016 (estimated)
  2. Study startJan 2015
  3. Primary completionJul 2016
  4. Study completionJul 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02855294
Sponsor's protocol ID
151
Status last verified
Aug 2016
First submitted
29 Jul 2016
Last updated
4 Aug 2016
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Yes

Publications

  • Maged AM, Salah E, Kamel AM, Hussein AM, Saad H, Meshaal H, Kamal WM. Effect of oral contraceptives on balance in women: A randomized controlled trial. Taiwan J Obstet Gynecol. 2017 Aug;56(4):463-466. doi: 10.1016/j.tjog.2017.02.003.

    PubMed 28805601

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing COC containing 30 μg of EE and 3mg of drospirenone in people with Joint Stabilioty, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

overall joint stability (time frame: 6 months after pill use). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02855294, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in